

# Therapeutics and Clinical Risk Management - 20<sup>th</sup> Anniversary

Garry M Walsh<sup>1</sup>, De Yun Wang<sup>2</sup>

<sup>1</sup>Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK; <sup>2</sup>Department of Otolaryngology, Yong Loo Lin School of Medicine, NUHS Tower Block, National University of Singapore, Singapore

Correspondence: Garry M Walsh, Email [g.m.walsh@abdn.ac.uk](mailto:g.m.walsh@abdn.ac.uk)

*Therapeutics and Clinical Risk Management* is fast approaching its 20<sup>th</sup> Anniversary having commenced publication in April 2005. Starting life as a print only publication the Journal was an early adopter of an online presence, moving towards the electronic-only, Open Access model soon after. Since inception, *Therapeutics and Clinical Risk Management* has grown into a highly regarded world-class international journal. The journal publishes original research articles, scholarly reviews and short opinion pieces focused on the role of therapeutics in clinical medicine in terms of efficacy, outcomes and safety including programs for the sustained use of medicines. Published articles include clinical studies or reviews in all therapeutic areas together with those that address our current understanding of disease pathology and management. Of particular interest are submissions that investigate or review the implications of treatments that are disease modifying rather than symptomatic in nature. All content published by the journal has been subjected to rigorous peer-review by acknowledged experts in the relevant speciality. The journal prides itself on the efficiency of the editorial process together with the fairness and speed of the complete process of submission, peer-review and, for accepted papers, rapidity of subsequent publication. Authors are kept up-to date on the status of their submitted paper on a regular basis. We believe the contents of *Therapeutics and Clinical Risk Management* to be of very high quality and that the journal is an important and increasingly high-profile asset to the medical community. This is emphasized by an Impact factor of 2.23, a CiteScore of 5.3 and 320,939 annual article downloads. The open access model adopted by *Therapeutics and Clinical Risk Management* ensures that all articles are quickly and efficiently available to as wide an audience as possible with no barriers to access. The key criterion for publication is a rigorous peer-review process overseen by the Editor-in-Chief with support from the Editorial board which ensures all papers are published solely on merit and otherwise worthy submissions are not rejected due to space constraints. There are many good reasons to consider for authors to submit their work to *Therapeutics and Clinical Risk Management* and also to other more specialised Journals in the Dove Medical Press stable ([Why Publish with Dove Medical Press? | Open Access Journals](#)). The broad remit of the Journal represents a very strong factor in the overall reach and contribution to our goal of improving clinical outcomes for patients. This is illustrated by the diverse conditions addressed by the three most cited articles<sup>1-3</sup> published over the last 25 years. A more recent initiative has been the development of a thematic series of Special Issues of the Journal that add to the literature in a more detailed and structured way. The current call for submissions to the Special Issues can be found at [Therapeutics and Clinical Risk Management | Call For Papers - Dove Press](#). The Editors would like to encourage potential authors to contact Catherine Teng ([catherine.teng@taylorandfrancis.com](mailto:catherine.teng@taylorandfrancis.com)) with possible ideas for Article Collections and also for review articles. Finally, we would like to hear from potential reviewers ([Register to become a peer-reviewer](#)) for the Journal and also from senior colleagues interested in applying to join the Editorial Board.

In summary, *Therapeutics and Clinical Risk Management* is an international, peer-reviewed open access journal of clinical therapeutics and risk management that provides an increasingly important resource to the medical community.

## Disclosure

Garry M Walsh and De Yun Wang are editors for *Therapeutics and Clinical Risk Management*. The authors report no other conflicts of interest in this work.



## References

1. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. *Therapeutics Clin Risk Manag.* 2008;4(1):269–286. doi:10.2147/TCRM.S1458
2. Yapar N. Epidemiology and risk factors for invasive candidiasis. *Therapeutics Clin Risk Manag.* 2014;95–105. doi:10.2147/TCRM.S40160
3. Al-Worafi YM, Kassab YW, Alseragi WM, et al. Pharmacovigilance and adverse drug reaction reporting: a perspective of community pharmacists and pharmacy technicians in Sana'a, Yemen. *Therapeutics Clin Risk Manag.* 2017;Volume 13:1175–1181. doi:10.2147/TCRM.S140674

Therapeutics and Clinical Risk Management

**Publish your work in this journal**

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/therapeutics-and-clinical-risk-management-journal>

**Dovepress**  
Taylor & Francis Group